These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression. Lu D; Han C; Wu T Gastroenterology; 2011 Jun; 140(7):2084-94. PubMed ID: 21354147 [TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Wehbe H; Henson R; Meng F; Mize-Berge J; Patel T Cancer Res; 2006 Nov; 66(21):10517-24. PubMed ID: 17079474 [TBL] [Abstract][Full Text] [Related]
7. Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Alpini G; Invernizzi P; Gaudio E; Venter J; Kopriva S; Bernuzzi F; Onori P; Franchitto A; Coufal M; Frampton G; Alvaro D; Lee SP; Marzioni M; Benedetti A; DeMorrow S Cancer Res; 2008 Nov; 68(22):9184-93. PubMed ID: 19010890 [TBL] [Abstract][Full Text] [Related]
8. Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Meng F; Wehbe-Janek H; Henson R; Smith H; Patel T Oncogene; 2008 Jan; 27(3):378-86. PubMed ID: 17621267 [TBL] [Abstract][Full Text] [Related]
9. Methyl-CpG binding protein MBD2 is implicated in methylation-mediated suppression of miR-373 in hilar cholangiocarcinoma. Chen Y; Gao W; Luo J; Tian R; Sun H; Zou S Oncol Rep; 2011 Feb; 25(2):443-51. PubMed ID: 21165562 [TBL] [Abstract][Full Text] [Related]
10. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma. Zheng T; Hong X; Wang J; Pei T; Liang Y; Yin D; Song R; Song X; Lu Z; Qi S; Liu J; Sun B; Xie C; Pan S; Li Y; Luo X; Li S; Fang X; Bhatta N; Jiang H; Liu L Hepatology; 2014 Mar; 59(3):935-46. PubMed ID: 24037855 [TBL] [Abstract][Full Text] [Related]
11. Trefoil factors: tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma. Kosriwong K; Menheniott TR; Giraud AS; Jearanaikoon P; Sripa B; Limpaiboon T World J Gastroenterol; 2011 Mar; 17(12):1631-41. PubMed ID: 21472131 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer. Liu T; Yang H; Fan W; Tu J; Li TWH; Wang J; Shen H; Yang J; Xiong T; Steggerda J; Liu Z; Noureddin M; Maldonado SS; Annamalai A; Seki E; Mato JM; Lu SC Gastroenterology; 2018 Aug; 155(2):557-571.e14. PubMed ID: 29733835 [TBL] [Abstract][Full Text] [Related]
13. Epigenetic alterations in cholangiocarcinoma-sustained IL-6/STAT3 signaling in cholangio- carcinoma due to SOCS3 epigenetic silencing. Isomoto H Digestion; 2009; 79 Suppl 1():2-8. PubMed ID: 19153483 [TBL] [Abstract][Full Text] [Related]
14. Molecular mechanism of monoamine oxidase A gene regulation under inflammation and ischemia-like conditions: key roles of the transcription factors GATA2, Sp1 and TBP. Gupta V; Khan AA; Sasi BK; Mahapatra NR J Neurochem; 2015 Jul; 134(1):21-38. PubMed ID: 25810277 [TBL] [Abstract][Full Text] [Related]
15. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Isomoto H; Kobayashi S; Werneburg NW; Bronk SF; Guicciardi ME; Frank DA; Gores GJ Hepatology; 2005 Dec; 42(6):1329-38. PubMed ID: 16317687 [TBL] [Abstract][Full Text] [Related]